Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

4 Aug 2011

Researchers sample hydrogenotrophic microbes in the healthy human colon

They make up less than one-hundredth of 1 percent of the microbes that live in the colon, but the bacteria and archaea that sop up hydrogen in the gut are fundamental to colon health. In a new study, researchers take a first look at these "hydrogenotrophic" microbes, mapping where they live and how abundant they are in different parts of the lower intestine.

3 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Metabolic syndrome linked to increased risk of primary liver cancers

22 Jul 2011

U.S.News ranks Rush University Medical Center among America's Best Hospitals for 2011-12

Rush University Medical Center has once again been named one of the nation's top hospitals in the nation, according to the upcoming issue of U.S.News & World Report.

21 Jul 2011

Big news for ankylosing spondylitis sufferers

In a medical breakthrough, researchers from the University of Queensland have found that there is a possible genetic link in a specific painful form of arthritis, which fuses bones in the spine and pelvis.

12 Jul 2011

New genetic research on Ankylosing Spondylitis

The team of researchers from the Universities of Bristol, Queensland, Oxford, Texas and Toronto, used a technique called genome-wide association where millions of genetic markers are measured in thousands of people that have the disease and thousands of healthy individuals.

11 Jul 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Train the brain to manage chronic pain

How do you function when chronic pain is a part of your daily life? The UC San Diego Center for Mindfulness (UCSD CFM) at UC San Diego Health System offers a novel program to help people who are dealing with chronic pain "train their brains" to lessen their experience of discomfort and, in some cases, eliminate it.

16 Jun 2011

Scientists identify potential target for reversing deadly blood infection sepsis

By digging a little deeper, researchers may have found a potential target for reversing the deadly blood infection sepsis.

13 Jun 2011

AGA honors outstanding high school students with 2011 research fellowship awards

The American Gastroenterological Association (AGA) Research Foundation has announced the 2011 Student Research Fellowship Award recipients. Funded by The Eli and Edythe Broad Foundation, the awards are intended to stimulate interest in research careers in digestive diseases.

10 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.

7 Jun 2011

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

The first study of the social and ethical issues associated with a provocative approach to treatment for ulcerative colitis has found that the majority of potential patients are eager for what is now called "fecal microbiota transplantation" to become available, although many have concerns about donor selection, screening, and methods of delivery.

3 Jun 2011

Shield raises EUR8.2M through Series A financing

Shield Therapeutics, the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has successfully raised EUR8.2m from Inventages Venture Capital (Inventages) in its first institutional financing round.

1 Jun 2011

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Avaxia receives BARDA contract to develop new radiation mitigation drug

Researchers sample hydrogenotrophic microbes in the healthy human colon

BARDA awards contracts for development of drugs for radiation injury to the GI tract

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Metabolic syndrome linked to increased risk of primary liver cancers

U.S.News ranks Rush University Medical Center among America's Best Hospitals for 2011-12

Big news for ankylosing spondylitis sufferers

New genetic research on Ankylosing Spondylitis

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Train the brain to manage chronic pain

Scientists identify potential target for reversing deadly blood infection sepsis

AGA honors outstanding high school students with 2011 research fellowship awards

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Majority of patients with ulcerative colitis eager to undergo fecal microbiota transplantation

Shield raises EUR8.2M through Series A financing

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in